Go or no go? UCB bids to make a mark in psoriasis
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Aerie brushes off dry eye trial failure
Bausch boosted ahead of eye spin-off
NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.
Remember Chantix? It’s back – for dry eye disease
The smoking-cessation drug, reformulated for nasal delivery, could be launched for dry eye, Oyster Point hopes.
Venture funding slowdown continues in first quarter of 2019
Venture funding drops again, but there’s no need to panic yet.